Struggling Heat gets a warm response to a snapshot on cancer vax data
Heat Biologics managed to at least temporarily extricate itself from penny stock territory after offering a positive update on its combination study for non-small cell lung cancer. Its stock surged more than 20% this morning based on an update for a handful of patients taking a combination of HS-110 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo.
The updated snapshot from the Durham, NC-based biotech included a note that 3 of 5 patients enrolled in a cohort for low tumor infiltrating lymphocytes “experienced significant tumor reduction, which is higher than the 10% response rate of low TIL patients reported for existing data on nivolumab alone.” 5 of 12 evaluable patients experienced an immune response to the combo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.